Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 20/20 | 0.86 |
| ▸ | ALK | Q9UM73 | 20/20 | 0.86 |
| ▸ | IGF1R | P08069 | 14/20 | 0.86 |
| ▸ | AURKA | O14965 | 2/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.85 |
| ▸ | PLK4 | O00444 | 1/20 | 0.85 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.85 |
| ▸ | PRKCG | P05129 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | CSF1R | P07333 | 1/20 | 0.85 |
| ▸ | LYN | P07948 | 1/20 | 0.85 |
| ▸ | RET | P07949 | 1/20 | 0.85 |
| ▸ | MET | P08581 | 1/20 | 0.85 |
| ▸ | ROS1 | P08922 | 1/20 | 0.85 |
| ▸ | KIT | P10721 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170709 | 1.00 | INSR (0.86) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL23635199 | 0.94 | INSR (0.87) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL30459865 | 0.94 | INSR (0.87) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL25272952 | 0.94 | INSR (0.87) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL26275691 | 0.93 | INSR (0.88) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL3511228 | 0.93 | INSR (1.00) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL26358559 | 0.93 | INSR (0.88) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL25398877 | 0.92 | INSR (0.83) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL30170763 | 0.92 | INSR (0.83) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL25398486 | 0.92 | INSR (0.83) | INSRALKIGF1RAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-115697989-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | INSR 2131/4885ALK 140/4885IGF1R 446/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | INSR 2131/4885ALK 140/4885IGF1R 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.